Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients

Haifeng Lu,Liang Chen,Xiaxia Pan,Yujun Yao,Hua Zhang,Xiaofei Zhu,Xiaobin Lou,Chunxia Zhu,Jun Wang,Lanjuan Li,Zhongwen Wu
DOI: https://doi.org/10.3389/fmed.2021.762930
IF: 3.9
2021-10-14
Frontiers in Medicine
Abstract:Background: Cirrhosis is a common chronic liver disease characterized by irreversible diffuse liver damage. Intestinal microbiome dysbiosis and metabolite dysfunction contribute to the development of cirrhosis. Lactitol (4-β-D-galactopyranosyl-D-glucitol) was previously reported to promote the growth of intestinal Bifidobacteria . However, the effect of lactitol on the intestinal microbiome and fecal short-chain fatty acids (SCFAs) and bile acids (BAs) and the interactions among these factors in cirrhotic patients pre- and post-lactitol treatment remain poorly understood. Methods: Here, using shotgun metagenomics and targeted metabolomics methods. Results: we found that health-promoting lactic acid bacteria, including Bifidobacterium longum, B.pseudocatenulatum , and Lactobacillus salivarius , were increased after lactitol intervention, and significant decrease of pathogen Klebsiella pneumonia and associated antibiotic resistant genes /virulence factors. Functionally, pathways including Pseudomonas aeruginosa biofilm formation, endotoxin biosynthesis, and horizontal transfer of pathogenic genes were decreased in cirrhotic patients after 4-week lactitol intervention compared with before treatment. Conclusion: We identified lactitol-associated metagenomic changes, and provide insight into the understanding of the roles of lactitol in modulating gut microbiome in cirrhotic patients.
medicine, general & internal
What problem does this paper attempt to address?